Merit Medical Systems Inc. Reports Strong Q3 2025 Earnings Amid Strategic Changes
Merit Medical Systems Inc. (NASDAQ: MMSI), a prominent player in the medical device industry, released its Q3 2025 financial results, showcasing a robust growth trajectory despite rising operating expenses and recent strategic adjustments. The company, renowned for its innovative medical devices used in interventional, diagnostic, and therapeutic procedures, reported notable increases in sales and profitability across its segments.
1. Financial Overview
For the three-month period ending September 30, 2025, Merit Medical reported total sales of $384.2 million, reflecting an increase of 13.0% from $339.8 million in the same quarter of 2024. This uptick is attributed to strong demand in the cardiovascular and endoscopy segments, marking a positive trend in the company’s overall performance.
Key Financial Metrics
- Net Income for Q3 2025: $27.8 million, or $0.46 per share, slightly down from $28.4 million or $0.48 per share in Q3 2024.
- Gross Profit Margin: Improved to 48.5% from 46.4% year-over-year.
- Sales for Nine Months: Reached $1,122.0 million, up 12.0% from $1,001.4 million in the previous year.
| Oct 2024 | Oct 2025 | |
|---|---|---|
Net Income | 120.0M | 118.4M |
Profit | 120.0M | 118.4M |
Net Income Continuing | 120.0M | 118.4M |
Income Tax Expense | 28.27M | 34.59M |
Pretax Income | 148.3M | 153.0M |
Non-operating Income | -4.42M | -14.06M |
Operating Income | 152.7M | 167.0M |
Revenue | 1.32B | 1.47B |
Costs and Expenses | 1.17B | 1.31B |
Cost of Revenue | 704.9M | 761.2M |
Operating Expenses | 468.1M | 548.8M |
Research & Development | 83.91M | 96.00M |
Selling, General & Administrative | 384.4M | 451.4M |
Other Operating Expenses | -181K | 1.34M |
2. Segment Performance
Cardiovascular Segment
The cardiovascular segment continues to be the backbone of Merit Medical's revenue generation. In Q3 2025, sales in this segment totaled $366.4 million, a 13.5% increase compared to $322.9 million in Q3 2024. For the nine-month period, cardiovascular sales reached $1,069.2 million, up 10.9% from $964.0 million the previous year.
Endoscopy Segment
Endoscopy sales showed significant growth as well, totaling $17.7 million for Q3, representing a 4.4% increase from $17.0 million in the same quarter last year. For the nine-month period, endoscopy sales surged to $52.8 million, marking a striking 41.5% increase due to heightened demand for the EsophyX® Z+ device.
3. Geographic Breakdown
U.S. Sales
U.S. sales for Q3 2025 were reported at $230.6 million, which accounts for 60.0% of net sales. This figure reflects an 11.7% increase from the prior year, driven primarily by strong performances in the U.S. Direct and OEM business segments.
International Sales
Merit Medical also saw robust performance internationally, with sales of $153.6 million in Q3, a 15.2% increase compared to $133.4 million in 2024. International sales constituted 40.0% of total net sales, emphasizing the company's expanding global footprint.
| Oct 2024 | Oct 2025 | |
|---|---|---|
Total Assets | 2.37B | 2.63B |
Total Current Assets | 1.07B | 985.5M |
Cash and Equivalents | 523.1M | 392.4M |
Net Inventories | 310.5M | 326.5M |
Accounts Receivable | 189.8M | 210.2M |
Non-trade Receivables | 15.32M | 19.06M |
Prepaid Expenses | 31.32M | 35.02M |
Other Current Assets | 8.18M | 2.15M |
Total Non-current Assets | 1.29B | 1.64B |
Intangible Assets | 771.6M | 1.04B |
Non-current Deferred Tax Assets | 7.25M | 16.28M |
Net PP&E | 389.6M | 418.0M |
Lease Assets | 68.86M | 88.49M |
Other Non-current Assets | 62.38M | 76.85M |
Total Liabilities and Equity | 2.37B | 2.63B |
Total Liabilities | 1.05B | 1.10B |
Total Current Liabilities | 201.0M | 230.4M |
Accounts Payable and Accrued Liabilities | 189.6M | 219.8M |
Current Debt | 11.46M | 10.61M |
Total Non-current Liabilities | 853.5M | 871.1M |
Long-term Debt | 750.5M | 732.9M |
Non-current Accounts Payable and Accrued Liabilities | 347K | 0 |
Non-current Deferred Revenue | 1.52M | 1.42M |
Non-current Deferred Compensation | 19.21M | 17.08M |
Non-current Deferred Tax Liabilities | 5.57M | 26.70M |
Other Non-current Liabilities | 76.43M | 92.98M |
Total Equity and Non-controlling Interests | 1.32B | 1.52B |
Total Equity | 1.32B | 1.52B |
4. Operational Insights
Operating Expenses
Operating expenses saw a significant rise due to increased selling, general, and administrative (SG&A) costs, which rose by 20.2% to $119.8 million in Q3. This uptick is largely attributed to labor-related costs, including variable compensation and headcount increases related to business growth.
Research and Development Investments
Investment in research and development (R&D) reached $24.0 million, up 16.8% from the previous year. This commitment to R&D highlights Merit Medical's focus on innovation and product advancement, which is crucial for maintaining its competitive edge in the medical device market.
5. Cash Flow and Financial Position
Merit Medical's cash flow statement for Q3 2025 revealed a net cash increase of $50.64 million, reflecting a strong operational cash flow of $74.98 million. The company continues to invest strategically, with $122.8 million spent on acquisitions in the first nine months of 2025, including the notable Biolife Merger.
| Oct 2024 | Oct 2025 | |
|---|---|---|
Net Change in Cash | 464.5M | -130.7M |
Effect of Exchange Rate Changes | 2.42M | -192K |
Net Cash from Operating Activities | 214.3M | 267.6M |
Operating Profit | 120.0M | 118.4M |
Adjustment to Operating Profit | 94.26M | 149.1M |
Net Cash from Investing Activities | -162.5M | -411.4M |
Business & Interest in Affiliates | 113.3M | 329.0M |
Investments | 7.66M | 18.70M |
Productive Assets | 41.57M | 63.76M |
Net Cash from Financing Activities | 410.3M | 13.36M |
Debt | 454.6M | -23M |
Equity Issuance/Repurchase | 19.56M | 47.66M |
Other Financing Activities | -63.83M | -11.29M |
6. Recent Developments
Merit Medical has undergone significant changes in its organizational structure, including a reorganization of its sales teams and product categories effective January 1, 2025. This restructuring aims to better align the company's resources with market demands, particularly integrating revenues from spine devices into the OEM product category.
Additionally, the company has made strides in product development and regulatory approvals, achieving CE mark for its Embosphere Microspheres for treating knee osteoarthritis, further enhancing its portfolio.
7. Conclusion
Merit Medical Systems Inc. demonstrated resilience and growth in its Q3 2025 financial performance, maintaining a strategic focus on innovation and market expansion. While operating expenses have risen, the company’s strong sales growth and commitment to R&D position it well for future success. As it continues to navigate the complexities of the medical device landscape, Merit Medical remains committed to enhancing patient outcomes through its diverse product offerings.
